Protocol H8A-MC-LZAZ(a)/ADC-040-A4 Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid.
In good general health, 65-85 years old, at risk for memory decline due to amyloid in the brain.
65 - 85
Healthy Volunteers Needed
Duration of Participation
Lisa Loree 503-494-7615
National Institute on Aging, Alzheimer's Disease Cooperative Studies, Eli Lilly and Co.
$25.00 for each completed clinical study visit and $25.00 for each completed infusion visit.